Alfuzosin PCD Pharma Franchise Company

Cafoli Lifecare offers an Alfuzosin PCD pharma franchise for distributors and stockists looking to build a urology portfolio. Our Alfuzosin range covers 4 tablet formulations, including the Alfuxyle brand and a fixed-dose combination with dutasteride. All products are made in WHO-GMP certified facilities and offered with monopoly distribution rights.

What is Alfuzosin?

Alfuzosin is a selective alpha-1 adrenoceptor antagonist used in benign prostatic hyperplasia (BPH). It blocks alpha-1 receptors concentrated in the smooth muscle of the prostate, bladder neck and prostatic urethra, relaxing that muscle and reducing the dynamic component of bladder outlet obstruction, which improves urinary flow and relieves lower urinary tract symptoms. It is described as functionally uroselective, meaning it acts on urinary tract receptors at doses that have relatively little effect on vascular tone. Full details are available at PubChem: Alfuzosin.

Alfuzosin Products Available for Franchise

These are featured presentations from a range of 4 formulations. Write to us for the complete Alfuzosin list and current pricing.

Therapeutic Applications of Alfuzosin

Alfuzosin is prescribed for the symptomatic management of benign prostatic hyperplasia — hesitancy, weak stream, straining, frequency, urgency and nocturia. The combination with dutasteride, a 5-alpha-reductase inhibitor that reduces prostate volume over time, addresses both the dynamic and the static components of obstruction in men with a significantly enlarged prostate.

These are prescription-only medicines, prescribed primarily by urologists, general physicians, geriatricians and consulting surgeons, and must be dispensed only against a valid prescription.

Why Alfuzosin is a High-Potential Molecule for Distributors

BPH is an age-linked condition, and India's over-50 male population is growing steadily — which means the prescriber base for this molecule expands year on year rather than fluctuating with season or outbreak. Treatment is also long-term and often lifelong, so a single patient started on alfuzosin represents months of continuing refills rather than a one-week course. The combination tablet is a particularly useful line commercially: it consolidates two drugs into one daily tablet, which improves adherence and is favoured by urologists managing men with larger prostates, and single-pill combinations typically face less price erosion at the counter than plain alpha-blockers do.

Why Choose Cafoli Lifecare

We offer monopoly rights by district or territory, WHO-GMP certified manufacturing and DCGI-approved products. Franchise partners receive complete promotional inputs — visual aids, product cards, samples, MR bags and prescription pads — along with transparent pricing and dependable supply. More than 1000+ partners across India already distribute Cafoli Lifecare products.

References

1. PubChem Compound Summary – Alfuzosin
2. PubMed – Alfuzosin in benign prostatic hyperplasia